Eli Lilly and Company (VIE:LLYC)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Basaglar Revenue	626.00M
Humalog Revenue	2.17B
Humulin Revenue	705.00M
Jardiance Revenue	3.43B
Mounjaro Revenue	22.97B
Trajenta Revenue	318.00M
Trulicity Revenue	4.28B
Zepbound Revenue	13.54B
Other Cardiometabolic Health Revenue	189.00M
Cardiometabolic Health Revenue	48.22B
Oncology Revenue	9.38B
Immunology Revenue	5.25B
Neuroscience Revenue	1.39B
Other Product Revenue	944.00M
Revenue (Other)	-
Revenue (Total)	65.18B

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
US Revenue	43.48B
Europe Revenue	11.56B
Japan Revenue	2.13B
China Revenue	1.95B
Other Foreign Countries Revenue	6.06B
Revenue (Other)	-
Revenue (Total)	65.18B

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
Revenue Change due to Price	-6.00%
Revenue Change due to Volume	50.00%
Revenue Change due to FX	1.00%

Updated Dec 31, 2025. Data Source: Fiscal.ai.